{
    "clinical_study": {
        "@rank": "119269", 
        "arm_group": [
            {
                "arm_group_label": "RPV + DRV/r", 
                "arm_group_type": "Experimental", 
                "description": "switch to RPV + DRV/r"
            }, 
            {
                "arm_group_label": "PI/ritonavir-containing antiretroviral triple drug therapy", 
                "arm_group_type": "Active Comparator", 
                "description": "the control arm will continue the protease inhibitor (PI)/r-containing triple drug therapy that is currently on-going."
            }
        ], 
        "brief_summary": {
            "textblock": "Clinical approach to HIV infection treatment is based on the use of highly active\n      antiretroviral therapies (HAART) and recent national and international guidelines for\n      guiding HIV therapy recommend the use of triple-combination therapy using antiretrovirals\n      with 2 nucleos(t)ide inhibitors [N(n)RTI] as backbone plus a third drug to be chosen among a\n      boosted protease inhibitor (PI/r), a nonnucleoside inhibitor (NNRTI) or an integrase\n      inhibitor (II).\n\n      In spite of evident efficacy of HAART, as demonstrated by survival increasing, long term\n      side effects, as for example the impact on renal function, remain principal problem.\n\n      In patient with risk factor for renal disease, a reduction of eGRF (estimated Glomerular\n      Filtration Rate) between 90 and 60 mL/min/1,73 m2 could be already considered as a risk\n      condition [1,2].\n\n      Efficacy of HAART, with increase of media survival and the parallel decrease of mortality,\n      has underlined the necessity to reflect on long term HAART effects [3].\n\n      There are many evidences of HAART-related toxicity that, in spite of the necessity of a\n      life-saving therapy, focus on the additional costs of this situation, in terms of health as\n      well as in terms of economic costs.\n\n      Particular attention has been focused on the impact of some drugs on renal function, as\n      tenofovir, especially on tubule, without forgetting the modification of lipid and bone\n      metabolisms.\n\n      According to further studies which have evidenced the potential of some recently introduced\n      molecules [4,5], the investigators had the need to realize a study to deepen the feasibility\n      of a dual-therapy that permit to exclude NRTIs from the backbone, with the aim to prevent\n      NRTIs-related long-term toxicity.\n\n      The investigators have designed a prospective randomized controlled trial, open-label, with\n      a duration of 96 weeks, to compare the efficacy of a dual-therapy based on rilpivirine 25mg\n      plus darunavir 800mg/ritonavir 100mg QD, in HIV-positive subjects with suppressed viremia\n      from at least 3 months. In fact, there are a few data about association of these drugs,\n      which it has been shown to be safe, well tolerated, and with a strong pharmacological\n      synergy, without nucleos(t)idic backbone, while the necessity to minimize the costs\n      toxicity-related is becoming increasingly compelling.\n\n      According to clinical experience and literature data, the investigators hope this study\n      shows positive results in term of immune-virological efficacy, as well as in term of\n      decrease of VACS index - a complex parameter which has the purpose to quantify general\n      organic decay - and markers of lipid and bone metabolism, in group which receives\n      dual-therapy versus the group with standard therapy.\n\n      These results could stimulate further studies on less aggressive and however effective\n      therapeutic regimens, with more sustainable biological and economic costs."
        }, 
        "brief_title": "DRV/r + RPV QD: Efficacy and Toxicity Reduction", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "HIV-positive Subjects With HIV-RNA <50 Copies/mL", 
        "condition_browse": {
            "mesh_term": "HIV Seropositivity"
        }, 
        "detailed_description": {
            "textblock": "Pilot, phase III prospective, randomized, open-label, multicentric controlled study, which\n      will offer a novel dual-therapy regimen including RPV 25mg + DRV 800mg/rtv 100mg QD to HIV+\n      subjects with suppressed viremia.\n\n      132 HIV+ subjects will be randomized, 1:1, to switch to RPV+DRV/r versus continue\n      triple-drug therapy. Subjects will be switched from any PI/r-containing regimen.\n\n      The duration of the study is 96 weeks and patients will be stratified according to their HCV\n      serostatus (Ab positive or negative), age (> or < 50 years), and immunological status\n      (CD4<200/\u00b5L; CD4=200-500/\u00b5L; CD4>500/\u00b5L). It is planned to enroll at least 30% of female\n      subjects.\n\n      Follow-up visits will be performed at 4, 8, 12, 24, 36, 48, 60, 72, and 96 weeks (laboratory\n      and physical examination).\n\n      Effectiveness will be measured by determination of HIV-RNA, safety will be evaluated by\n      determination of AST, ALT, creatinine, plasmatic and urinary phosphate, albuminuria, total\n      cholesterol, HDL and LDL cholesterol, triglycerides at the follow-up visits."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult HIV+ subjects (>18 years old), giving and signing an informed consent;\n\n          -  Any HAART treatment for at least 12 months;\n\n          -  Current treatment with a PI/r-containing regimen initiated at least 6 months earlier;\n\n          -  HIV-RNA <50 cp/mL for at least 3 months, without viral blip due to virologic failure\n             at any time;\n\n          -  Any nadir CD4 lymphocytes;\n\n          -  Current CD4 count > 100 cell/uL;\n\n          -  eGFRs >60 mL/min/1.73 m2.\n\n        Exclusion Criteria:\n\n          -  Previous drug resistance genotypic test showing the presence of any RPV (RT: K101E/P,\n             E138A/G/K/Q/R, V179L, Y181C/I/V, Y188L, H221Y, F227C, M230I/L) or DRV (protease:\n             V11I, V32I, L33F, I47V, I50V, I54M/L, T74P, L76V, I84V, L89V) resistance associated\n             mutation (RAM), according to the November 2011 IAS-USA list;\n\n          -  Child-Pugh C or grade 3-4 AST or ALT values;\n\n          -  Acute cardiovascular event within 6 months;\n\n          -  AIDS event within 6 months;\n\n          -  Current IVDU;\n\n          -  HBsAg +;\n\n          -  Pregnancy or lactation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "132", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01792570", 
            "org_study_id": "HLS03/2012"
        }, 
        "intervention": [
            {
                "arm_group_label": "RPV + DRV/r", 
                "intervention_name": "RPV + DRV/r", 
                "intervention_type": "Drug", 
                "other_name": [
                    "RVP: rilpivirine; brand name: EdurantTM.", 
                    "DRV: darunavir; brand name: PrezistaTM."
                ]
            }, 
            {
                "arm_group_label": "PI/ritonavir-containing antiretroviral triple drug therapy", 
                "intervention_name": "subjects will continue the PI/r-containing regimen that is on-going at the time of enrollment.", 
                "intervention_type": "Drug", 
                "other_name": "the drugs will depend on the successful regimen that is already administerd to the enrolled subject."
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Darunavir"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV-1", 
            "darunavir", 
            "rilpivirine", 
            "strategic study"
        ], 
        "lastchanged_date": "February 14, 2013", 
        "location": [
            {
                "contact": {
                    "email": "g.angarano@clininf.uniba.it", 
                    "last_name": "Gioacchino Angarano, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Bari", 
                        "country": "Italy", 
                        "state": "BA"
                    }, 
                    "name": "Clinica delle Malattie Infettive, Policlinico Universitario"
                }, 
                "investigator": {
                    "last_name": "Gioacchino Angarano, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "sergio.locaputo@asf.toscana.it", 
                    "last_name": "Sergio Lo Caputo, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Firenze", 
                        "country": "Italy", 
                        "state": "FI"
                    }, 
                    "name": "Divisione di Malattie Infettive, Ospedale S. Maria Annunziata, Antella"
                }, 
                "investigator": {
                    "last_name": "Sergio Lo Caputo, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "antonio.dibiagio@hsanmartino.it", 
                    "last_name": "Antonio Di Biagio, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Genova", 
                        "country": "Italy", 
                        "state": "GE"
                    }, 
                    "name": "Clinica delle Malattie Infettive, Ospedale San Martino, Universit\u00e0 degli Studi"
                }, 
                "investigator": {
                    "last_name": "Antonio Di Biagio, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "andrea.gori@unimib.it", 
                    "last_name": "Andrea Gori, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Monza", 
                        "country": "Italy", 
                        "state": "MB"
                    }, 
                    "name": "Divisione di Malattie Infettive, Ospedale San Gerardo"
                }, 
                "investigator": {
                    "last_name": "Andrea Gori, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rizzardini.giuliano@hsacco.it", 
                    "last_name": "Giuliano Rizzardini, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20157"
                    }, 
                    "name": "I e II Divisione Malattie Infettive, Azienda Ospedaliera-Polo Universitario \"Luigi Sacco\""
                }, 
                "investigator": {
                    "last_name": "Giuliano Rizzardini, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "stefano.rusconi@unimi.it", 
                    "last_name": "Stefano Rusconi, M.D."
                }, 
                "contact_backup": {
                    "email": "elisa_colella@yahoo.it", 
                    "last_name": "Elisa Colella, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Milano", 
                        "country": "Italy", 
                        "state": "MI", 
                        "zip": "20157"
                    }, 
                    "name": "Divisione Clinicizzata di Malattie Infettive dell'Universit\u00e0 degli Studi, Dipartimento di Scienze Biomediche e Cliniche \"Luigi Sacco\""
                }, 
                "investigator": {
                    "last_name": "Stefano Rusconi, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "crimuss@unimore.it", 
                    "last_name": "Cristina Mussini, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Modena", 
                        "country": "Italy", 
                        "state": "MO"
                    }, 
                    "name": "Clinica Malattie Infettive, Policlinico Universitario"
                }, 
                "investigator": {
                    "last_name": "Cristina Mussini, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rmaserati@smatteo.pv.it", 
                    "last_name": "Renato Maserati, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Pavia", 
                        "country": "Italy", 
                        "state": "PV"
                    }, 
                    "name": "U.O. Malattie Infettive, Policlinico S. Matteo"
                }, 
                "investigator": {
                    "last_name": "Renato Maserati, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "vincenzo.vullo@uniroma1.it", 
                    "last_name": "Vincenzo Vullo, M.D."
                }, 
                "contact_backup": {
                    "email": "gabriella.dettorre@uniroma1.it", 
                    "last_name": "Gabriella D'Ettorre, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "RM"
                    }, 
                    "name": "U.O. Malattie Infettive, Azienda Policlinico Umberto I, Universit\u00e0 degli Studi \"La Sapienza\""
                }, 
                "investigator": {
                    "last_name": "Vincenzo Vullo, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "simona.digiambenedetto@rm.unicatt.it", 
                    "last_name": "Simona Di Giambenedetto, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "RM"
                    }, 
                    "name": "Istituto di Clinica delle Malattie Infettive, Universit\u00e0 Cattolica del Sacro Cuore"
                }, 
                "investigator": {
                    "last_name": "Simona Di Giambenedetto, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "andreoni@uniroma2.it", 
                    "last_name": "Massimo Andreoni, M.D."
                }, 
                "contact_backup": {
                    "email": "sarmati@med.uniroma2.it", 
                    "last_name": "Loredana Sarmati, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "state": "RM"
                    }, 
                    "name": "Clinica delle Malattie Infettive, Policlinico \"Tor Vergata\""
                }, 
                "investigator": {
                    "last_name": "Massimo Andreoni, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "stefano.bonora@unito.it", 
                    "last_name": "Stefano Bonora, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "state": "TO"
                    }, 
                    "name": "Clinica delle Malattie Infettive, Ospedale Amedeo di Savoia, Universit\u00e0 degli Studi"
                }, 
                "investigator": {
                    "last_name": "Stefano Bonora, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Strategic Study of Dual-therapy With Darunavir/Ritonavir and Rilpivirine QD Versus Triple-therapy in Patients With Suppressed Viral Load: Virological Efficacy and Evaluation of Non-HIV Related Morbidity.", 
        "overall_contact": {
            "email": "stefano.rusconi@unimi.it", 
            "last_name": "Stefano - Rusconi, M.D.", 
            "phone": "0039 02 39042949"
        }, 
        "overall_official": {
            "affiliation": "DIBIC \"Luigi Sacco\", Universit\u00e0 degli Studi di Milano, Italy", 
            "last_name": "Stefano - Rusconi, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Italy: National Monitoring Centre for Clinical Trials - Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Responders: HIV+ subjects with HIV-RNA < 50 cp/mL at week 48 according to the intention-to-treat (ITT-TLOVR) approach.", 
            "measure": "HIV-RNA < 50 cp/mL", 
            "safety_issue": "No", 
            "time_frame": "Week 48"
        }, 
        "reference": [
            {
                "PMID": "22297503", 
                "citation": "Maggi P, Bartolozzi D, Bonfanti P, Calza L, Cherubini C, Di Biagio A, Marcotullio S, Montella F, Montinaro V, Mussini C, Narciso P, Rusconi S, Vescini F. Renal complications in HIV disease: between present and future. AIDS Rev. 2012 Jan-Mar;14(1):37-53. Review."
            }, 
            {
                "PMID": "22312131", 
                "citation": "Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med. 2012 Jun 5;156(11):785-95, W-270, W-271, W-272, W-273, W-274, W-275, W-276, W-277, W-278. doi: 10.7326/0003-4819-156-6-201203200-00391. Epub 2012 Feb 6. Review."
            }, 
            {
                "PMID": "20018391", 
                "citation": "Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010 Jan;85(1):1-18. doi: 10.1016/j.antiviral.2009.10.002. Epub 2009 Dec 16. Review."
            }, 
            {
                "PMID": "22378681", 
                "citation": "Burgos J, Crespo M, Falc\u00f3 V, Curran A, Imaz A, Domingo P, Podzamczer D, Mateo MG, Van den Eynde E, Villar S, Ribera E. Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretroviral regimen. J Antimicrob Chemother. 2012 Jun;67(6):1453-8. doi: 10.1093/jac/dks057. Epub 2012 Feb 29."
            }, 
            {
                "PMID": "21187353", 
                "citation": "Clumeck N, Cahn P, Molina JM, Mills A, Nijs S, Vingerhoets J, Witek J. Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials. Int J STD AIDS. 2010 Nov;21(11):738-40. doi: 10.1258/ijsa.2010.010139."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01792570"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ospedale L. Sacco - Polo Universitario", 
            "investigator_full_name": "Stefano Rusconi", 
            "investigator_title": "Researcher/Aggregate professor in infectious diseases", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Safety will be assessed through the number of ACTG grade III and IV in the specified safety parameters.", 
            "measure": "ACTG grade III and IV events.", 
            "safety_issue": "Yes", 
            "time_frame": "over 96 weeks."
        }, 
        "source": "Ospedale L. Sacco \u2013 Polo Universitario", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Elisa Colella, M.D.", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Valentina Di Cristo, M.D.", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Massimo Galli, M.D.", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Ospedale L. Sacco \u2013 Polo Universitario", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}